1.Methodological establishment of red blood cell lysis method for handling Rh typing double group samples
Lu LI ; Bin WANG ; Junjie WEI ; Xiaolin SUN ; Haiyun LIU ; Weixin WU ; Yinze ZHANG
Chinese Journal of Blood Transfusion 2026;39(1):114-117
Objective: To establish an accurate and rapid typing method for Rh typing of samples from patients who have received recent blood transfusions by utilizing the difference in osmotic fragility between fresh and old red blood cells. Methods: A lysing solution suitable for destroying old RBCs was prepared. Sixty-one samples collected in our hospital in 2024 with Rh typing of double groups were treated with the lysing solution to remove the old allogeneic red blood cells while preserving the patient's own fresh red blood cells, followed by repeat Rh typing tests. Results: For 61 samples with Rh typing in double groups, 41 were accurately detected identified through the red blood cell lysis method, yielding an identification rate of 67.21%. No significant difference was observed compared to the detection rate of the commonly used capillary centrifugation modified method (χ
=0.103, P>0.05). Conclusion: The red blood cell lysis method provides a novel and rapid experimental approach for clinical use in processing Rh-typed samples that are of double groups, thereby offering a basis for Rh compatibility blood transfusion.
2.Analysis and study on clinical blood transfusion of 4 157 patients with emergency transfusion
Jie SUN ; Yunhua SUN ; Renyu WANG ; Gang FAN ; Hongji FAN ; Dongfu XIE ; Junjie LIN
Chinese Journal of Blood Transfusion 2026;39(2):203-208
Objective: To provide evidence for improving emergency blood supply protocols by analyzing the clinical characteristics and disease distribution of emergency transfusion patients, especially those receiving≥10 units of red blood cells (RBCs). Methods: The data of 4 157 patients who urgently applied for large-volume blood transfusion in various hospitals in Shanghai from May 2024 to April 2025 were selected and analyzed statistically. Results: Tertiary gradeA hospitals accounted for the largest proportion of total transfusion volume (U) (48.79%, 8 420/17 256.5), with no statistically significant differences in RBC transfusion volumes among hospitals of different grades (P>0.05). All blood products are most widely used in tertiary hospitals. Obstetric blood transfusion (U)(19.07%, 3 277.5/17 190.5) was the most frequent. A-mong the hospitals of patients who received emergency blood transfusion with red blood cell suspension≥10 U, tertiary gradeA hospitals also had the largest transfusion volume (U)(47.19%, 1 107/2 346). In terms of disease types, the top three diseases in terms of blood transfusion volume (U) were obstetric transfusion (24.59%, 572/2 326), digestive diseases (14.53%, 338/2 326) and tumors (14.19%, 330/2 326). Conclusion: Tertiary grade A hospitals are the main demand units for emergency blood transfusion, with pregnant women and cancer patients being the core blood-using groups. It is suggested that the safety, timeliness and sufficiency of emergency blood transfusion be guaranteed by establishing a hierarchical blood supply mechanism, formulating single-disease blood transfusion plans and promoting precise blood transfusion guided by thromboelastography.
3.Ginsenoside Rg2 Protects Heart After Acute Myocardial Infarction by Regulating PI3K/Akt/mTOR Signaling Pathway
Xixian ZHANG ; Junjie SUN ; Qingya LIU
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(10):185-193
ObjectiveTo investigate the cardioprotective effects of ginsenoside Rg2 in regulating the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway following acute myocardial infarction (AMI) in rats. Methods(1) Cellular experiment: Cardiomyocytes were isolated from 24-hour-old Sprague-Dawley (SD) neonatal rats and subjected to primary culture. An in vitro model of cardiomyocytes under an ischemic-hypoxic microenvironment was established. Cardiomyocytes were pretreated with ginsenoside Rg2 (1, 2, 3 mg·L-1) for 4 hours, then placed in RPMI 1640 serum-free medium and cultured for 24 hours in a three-gas incubator (94% N2, 5% CO2, 1% O2). The survival rate of cardiomyocytes was assessed using the methyl thiazolyl terazolium (MTT) assay. The levels of lactate dehydrogenase (LDH) leakage, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity, and malondialdehyde (MDA) content in the cell culture supernatant were measured using spectrophotometry. (2) Animal experiment: Specific-pathogen-free (SPF) SD rats were used to establish an AMI model using the Olivette method combined with previous studies. Rats that survived 24 hours post-surgery were randomly divided into a model group and ginsenoside Rg2 high-, medium-, and low-dose groups. The normal and model groups received normal saline, while the ginsenoside Rg2 groups were administered intragastrically at doses of 8, 4, and 2 mg·kg-1, once daily for 3 days. The levels of SOD, MDA, and GSH-Px in myocardial tissues were detected. Cardiomyocyte apoptosis was assessed using the TdT-mediated dUTP biotin nick end labeling (TUNEL) assay. The mRNA and protein expression levels of PI3K, Akt, mTOR, p62, nuclear factor-κB p65 (NF-κB p65), and microtubule-associated protein 1 light chain 3 (LC3) Ⅱ/Ⅰ in myocardial tissues were analyzed using real-time quantitative polymerase chain reaction (Real-time PCR) and Western blot. Pathological changes in the infarct border zone were observed under a light microscope. Results(1) Cellular experiment: Compared with the normal group, the model group exhibited a significantly decreased cardiomyocyte survival rate, as well as reduced SOD and GSH-Px activity, whereas LDH activity and MDA content were significantly increased (P<0.05). Compared with the model group, ginsenoside Rg2 intervention significantly increased cardiomyocyte survival, SOD activity, and GSH-Px activity, while reducing LDH activity and MDA content (P<0.05) in a dose-dependent manner. Pathological examination revealed that ginsenoside Rg2 alleviated infarct size, myocardial degeneration, and necrosis, while significantly reducing cardiomyocyte apoptosis. (2) Animal experiment: Compared with the normal group, the model group exhibited significantly lower SOD and GSH-Px activity (P<0.05) and higher MDA content (P<0.05) in myocardial tissues. Compared with the model group, all ginsenoside Rg2 groups showed significantly increased SOD and GSH-Px activity (P<0.05) and reduced MDA content (P<0.05). Compared with the normal group, the model group exhibited significantly decreased mRNA and protein expression levels of PI3K, Akt, mTOR, p62,and LC3 Ⅱ/Ⅰ,whereas the expression levels of NF-κB p65 were significantly increased (P<0.05). Compared with the model group, the ginsenoside Rg2 groups showed significantly increased PI3K, Akt, mTOR, and p62 expression, while NF-κB p65 expression levels were significantly decreased (P<0.05) in a dose-dependent manner,the mRNA and protein expression levels of LC3 Ⅱ/Ⅰ in ginsenoside Rg2 high-dose groups were significantly increased(P<0.05). ConclusionGinsenoside Rg2 exerts cardioprotective effects following AMI in rats, potentially through the regulation of PI3K/Akt/mTOR-related protein expression.
4.Research progress in antibody drug therapy for relapsed/refractory diffuse large B-cell lymphoma
Yanyan SUN ; Weichen ZHAO ; Chunyuan HE ; Yimiao XIA ; Wei ZHOU ; Yuanyuan ZHEN ; Junjie JIANG ; Facai WANG
China Pharmacy 2025;36(13):1677-1682
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease. Although standard first-line regimens can cure >50% of patients, approximately one-third of them develop relapsed/refractory DLBCL (r/r DLBCL). Consequently, immunotherapy targeting molecular abnormalities has become pivotal for managing r/r DLBCL. The results of this review show that with advances in understanding DLBCL pathogenesis and the tumor immune microenvironment, antibody-based therapies have evolved rapidly, progressing from monoclonal antibodies (e.g., rituximab, tafasitamab) to bispecific antibodies(e.g., odronextamab,glofitamab, epcoritamab) and antibody-drug conjugate (e.g., polatuzumab vedotin, loncastuximab tesirine). These engineered agents enhance immune cytotoxicity and tumor-specific targeting, providing novel therapeutic options for r/r DLBCL patients.
5.Effect of electroacupuncture on intestinal function after gastric cancer surgery.
Junjie GUAN ; Miaomiao GE ; Yuling CAI ; Ting WANG ; Zhiwei JIANG ; Jianhua SUN ; Gang WANG
Chinese Acupuncture & Moxibustion 2025;45(6):751-756
OBJECTIVE:
To observe the effect of electroacupuncture combined with enhanced recovery after surgery (ERAS) protocol on promoting intestinal function in patients after gastric cancer surgery.
METHODS:
Forty-four patients who underwent radical gastrectomy for gastric cancer were randomly divided into an experimental group (22 cases, 3 cases were excluded) and a control group (22 cases, 4 cases were excluded). Both groups received treatment under ERAS protocol, the experimental group was given electroacupuncture at bilateral Neiguan (PC6), Hegu (LI4), Zusanli (ST36) and Quchi (LI11), disperse-dense wave was selected, with frequency of 2 Hz/100 Hz. The control group received placebo electroacupuncture intervention, with the same acupoints as the experimental group, electrode pads were placed on the acupoints without electrical stimulation. Each session lasted 30 min, starting from 1 h after surgery, once every 24 h, until the patient resumed anal flatus. The intestinal sound rate of both groups was observed 24 h before surgery and 24, 48 h after surgery. The bowel sound recovery time (BSRT), time to first anal flatus, time to first defecation, and tolerance to oral enteral nutrition suspension were compared between the two groups. The levels of serum C-reactive protein (CRP), interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, IL-17, tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) were measured 24 h before surgery and 24 h after surgery in both groups.
RESULTS:
The intestinal sound rate 24 h after surgery was decreased compared with that 24 h before surgery in the two groups (P<0.05), the intestinal sound rate 24, 48 h after surgery in the experimental group was higher than that in the control group (P<0.05). The BSRT in the experimental group was earlier than that in the control group (P<0.05) .The levels of serum CRP, IL-6, IL-10 24 h after surgery in the experimental group were higher than those 24 h before surgery (P<0.05), while the levels of serum CRP, IL-4, IL-6, IL-10, IFN-γ in the control group were higher than those 24 h before surgery (P<0.05); the levels of serum CRP、IL-4、IFN-γ 24 h after surgery in the experimental group were lower than those in the control group (P<0.05) .The tolerance rate of oral enteral nutrition suspension in the experimental group was 84.2% (16/19), which was higher than 50.0% (9/18) in the control group (P<0.05).
CONCLUSION
Electroacupuncture combined with ERAS protocol can improve the intestinal motility, shorten the BSRT, enhance the tolerance of oral intake, and reduce inflammatory response in patients after gastric cancer surgery.
Adult
;
Aged
;
Female
;
Humans
;
Male
;
Middle Aged
;
Acupuncture Points
;
C-Reactive Protein/metabolism*
;
Electroacupuncture
;
Gastrectomy
;
Interleukin-10
;
Interleukin-6
;
Intestines/physiopathology*
;
Stomach Neoplasms/therapy*
6.A novel glycolysis-related prognostic risk model for colorectal cancer patients based on single-cell and bulk transcriptomic data.
Kai YAO ; Jingyi XIA ; Shuo ZHANG ; Yun SUN ; Junjie MA ; Bo ZHU ; Li REN ; Congli ZHANG
Chinese Journal of Cellular and Molecular Immunology 2025;41(2):105-115
Objective To explore the prognostic value of glycolysis-related genes in colorectal cancer (CRC) patients and formulate a novel glycolysis-related prognostic risk model. Methods Single-cell and bulk transcriptomic data of CRC patients, along with clinical information, were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Glycolysis scores for each sample were calculated using single-sample Gene Set Enrichment Analysis (ssGSEA). Kaplan-Meier survival curves were generated to analyze the relationship between glycolysis scores and overall survival. Novel glycolysis-related subgroups were defined among the cell type with the highest glycolysis scores. Gene enrichment analysis, metabolic activity assessment, and univariate Cox regression were performed to explore the biological functions and prognostic impact of these subgroups. A prognostic risk model was built and validated based on genes significantly affecting the prognosis. Gene Set Enrichment Analysis (GSEA) was conducted to explore differences in biological processes between high- and low-risk groups. Differences in immune microenvironment and drug sensitivity between these groups were assessed using R packages. Potential targeted agents for prognostic risk genes were predicted using the Enrichr database. Results Tumor tissues showed significantly higher glycolysis scores than normal tissues, which was associated with a poor prognosis in CRC patients. The highest glycolysis score was observed in epithelial cells, within which we defined eight novel glycolysis-related cell subpopulations. Specifically, the P4HA1+ epithelial cell subpopulation was associated with a poor prognosis. Based on signature genes of this subpopulation, a six-gene prognostic risk model was formulated. GSEA revealed significant biological differences between high- and low-risk groups. Immune microenvironment analysis demonstrated that the high-risk group had increased infiltration of macrophages and tumor-associated fibroblasts, along with evident immune exclusion and suppression, while the low-risk group exhibited higher levels of B cell and T cell infiltration. Drug sensitivity analysis indicated that high-risk patients were more sensitive to Abiraterone, while low-risk patients responded to Cisplatin. Additionally, Valproic acid was predicted as a potential targeted agent. Conclusion High glycolytic activity is associated with a poor prognosis in CRC patients. The novel glycolysis-related prognostic risk model formulated in this study offers significant potential for enhancing the diagnosis and treatment of CRC.
Humans
;
Colorectal Neoplasms/pathology*
;
Glycolysis/genetics*
;
Prognosis
;
Transcriptome
;
Tumor Microenvironment/genetics*
;
Gene Expression Profiling
;
Single-Cell Analysis
;
Gene Expression Regulation, Neoplastic
;
Male
;
Female
;
Kaplan-Meier Estimate
7.Locally producing antibacterial peptide to deplete intratumoral pathogen for preventing metastatic breast cancer.
Shizhen GENG ; Tingting XIANG ; Yaru SHI ; Mengnian CAO ; Danyu WANG ; Jing WANG ; Xinling LI ; Haiwei SONG ; Zhenzhong ZHANG ; Jinjin SHI ; Junjie LIU ; Airong LI ; Ke SUN
Acta Pharmaceutica Sinica B 2025;15(2):1084-1097
Metastatic dissemination is the major cause of death from breast-cancer (BC). Fusobacterium nucleatum (F.n) is widely enriched in BC and has recently been identified as one of the high-risk factors for promoting BC metastasis. Here, with an experimental model, we demonstrated that intratumoral F.n induced BC aggressiveness by transcriptionally activating Epithelial-mesenchymal transition-associated genes. Therefore, the F.n may be a potential target to prevent metastasis. Given the fact that cancer-associated fibroblasts (CAFs) are abundant in BC and located near blood vessels, we report an optogenetic system that drives CAF to in situ produce human antibacterial peptide LL37, with the characteristics of biosafety and freely intercellular trafficking, for depleting intratumoral F.n, leading to a 72.1% reduction in lung metastatic nodules number without affecting the balance of the systemic flora. Notably, mild photothermal treatment was found that could normalize CAF, contributing to synergistically inhibiting BC metastasis. In addition, the system can also simultaneously encode a gene of TNF-related apoptosis-inducing ligand to suppress the primary tumor. Together, our study highlights the potential of local elimination of tumor pathogenic bacteria to prevent BC metastasis.
8.Construction and optimization of 1, 4-butanediamine biosensor based on transcriptional regulator PuuR.
Junjie LIU ; Minmin JIANG ; Tong SUN ; Xiangxiang SUN ; Yongcan ZHAO ; Mingxia GU ; Fuping LU ; Ming LI
Chinese Journal of Biotechnology 2025;41(1):437-447
Biosensors have become powerful tools for real-time monitoring of specific small molecules and precise control of gene expression in biological systems. High-throughput sensors for 1, 4-butanediamine biosynthesis can greatly improve the screening efficiency of high-yielding 1, 4-butanediamine strains. However, the strategies for adapting the characteristics of biosensors are still rarely studied, which limits the applicability of 1, 4-butanediamine biosensors. In this paper, we propose the development of a 1, 4-butanediamine biosensor based on the transcriptional regulator PuuR, whose homologous operator puuO is installed in the constitutive promoter PgapA of Escherichia coli to control the expression of the downstream superfolder green fluorescent protein (sfGFP) as the reporter protein. Finally, the biosensor showed a stable linear relationship between the GFP/OD600 value and the concentration of 1, 4-butanediamine when the concentration of 1, 4-butanediamine was 0-50 mmol/L. The promoters with different strengths in the E. coli genome were used to modify the 1, 4-butanediamine biosensor, and the functional properties of the PuuR-based 1, 4-butanediamine biosensor were explored and improved, which laid the groundwork for high-throughput screening of engineered strains highly producing 1, 4-butanediamine.
Biosensing Techniques/methods*
;
Escherichia coli/metabolism*
;
Promoter Regions, Genetic/genetics*
;
Green Fluorescent Proteins/metabolism*
;
Transcription Factors/genetics*
;
Escherichia coli Proteins/genetics*
;
Diamines/metabolism*
;
Gene Expression Regulation, Bacterial
9.Design of a mammography X-ray image classification assistant system adapted to Chinese population
Changjin SUN ; Fei TONG ; Yi WU ; Yuting WANG ; Junjie LUO ; Yan GONG ; Mingguo QIU ; Liang QIAO
Journal of Army Medical University 2025;47(1):92-99
Objective To construct a mammography image classification assistant system suitable for Chinese population,and explore the potential of artificial intelligence technology to assist early screening of breast cancer in China.Methods Curated breast imaging subset of digital database for screening mammography(CBIS-DDSM),Mammographic image analysis society database(MIAS)and other international open datasets were used to conduct model training respectively in order to reproduce the mainstream in-depth learning methods in the current literature.The model was also tested on the Chinese breast mammography database(CBMD)provided by Huajiao Technology Co.,Ltd,and the performance was compared.Aiming at the problem that the Chinese population data are not ideal in the performance test of the open dataset training model,an optimization strategy based on the sliding window adjustment mechanism was implemented in combination with the characteristics of Chinese population data.Then a two-stage migration learning method was designed to improve the overall performance of the model,and then development of our system was carried out.Results With the sliding window adjustment mechanism and the CBMD training model after two-stage transfer learning,the accuracy of our developed system was improved from 0.50 of the open datasets to 0.80,precision from 0.54 to 0.82,sensitivity from 0.52 to 0.80,F1 value from 0.52 to 0.80,and AUC value from 0.51 to 0.89 based on the Chinese population dataset as the test set.Conclusion Through the introduction of sliding window adjustment mechanism and two-stage migration learning strategy,the performance of the breast molybdenum target image classification model has been significantly improved in the Chinese population dataset,and our system primarily achieves the purpose of assisting the classification of breast molybdenum target images for the Chinese population.
10.Research Progress in the Diagnosis and Treatment of Pancreatic Acinar Cell Carcinoma
Wenfei LI ; Yuan XIE ; Liyang MO ; Junjie DANG ; Qi WANG ; Yang YANG ; Qiuying SUN ; Zhenping WEN ; Sai GE ; Xiaotian ZHANG
JOURNAL OF RARE DISEASES 2025;4(4):437-445
Pancreatic acinar cell carcinoma (PACC) is a rare exocrine tumor of the pancreas with distinct clinical and pathological features. In recent years, advancements in molecular biology techniques have led to a deeper understanding of the molecular mechanisms underlying PACC. Progress in imaging, endoscopic, and molecular diagnostic technologies has improved the early detection rate of PACC. The primary treatment modalities for PACC include surgical resection, chemotherapy, targeted therapy and immunotherapy; however, the therapeutic efficacy still requires further improvement. This article reviews the current research status of PACC, covering its epidemiology, pathological characteristics, molecular alterations, diagnostic methods, and treatment strategies, and discusses the controversies and future directions in PACC research.

Result Analysis
Print
Save
E-mail